NCT03146884 Swiss Autoimmune Hepatitis Cohort Study
| NCT ID | NCT03146884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Epatocentro Ticino |
| Condition | Hepatitis, Autoimmune |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2017-02-16 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2017-02-16 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Research project in which biological material is sampled and health-related personal data is further used and collected. Coded data are used.
Eligibility Criteria
Inclusion Criteria: * diagnosis of AIH, either type I or type II * Only patients living in Switzerland Exclusion Criteria: * N/A
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03146884 clinical trial?
This trial is open to participants of all sexes, studying Hepatitis, Autoimmune. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03146884 currently recruiting?
Yes, NCT03146884 is actively recruiting participants. Contact the research team at andreas.cerny@hin.ch for enrollment information.
Where is the NCT03146884 trial being conducted?
This trial is being conducted at Lugano, Switzerland, Basel, Switzerland, Basel, Switzerland, Bern, Switzerland and 11 additional locations.
Who is sponsoring the NCT03146884 clinical trial?
NCT03146884 is sponsored by Fondazione Epatocentro Ticino. The trial plans to enroll 500 participants.